Abstract:The V600E-BRAF protein kinase is a promising and essential therapeutic target in melanoma and other types of tumors. However, its resistance to known inhibitors, as well as the side effects of some identified inhibitors, necessitates the search for new and potent inhibitors. In this study, in-silico strategies such as Molecular-docking simulation, DFT (Density-Functional-Theory) computations, and Pharmacokinetic evaluation were used to identify potential V600E-BRAF inhibitors from a set of 38 novel imidazole analogs with terminal sulphonamides. The docking results showed that five compounds (4, 15, 24, 26, and 27), had remarkable docking score (MolDock-score of -186.01, -180.58, -170.89, -177.24 and − 189.24 kcalmol− 1 and Rerank-score of -132.79, -144.43, -136.56, -140.15 and − 136.74 kcalmol− 1) and appeared to be the most active and potent V600E-BRAF inhibitors than Vemurafenib (-158.14 kcalmol− 1 and − 118.61 kcalmol− 1). The high stability of these complexes was demonstrated by H-bond formation and hydrophobic interactions with essential residues of V600E-BRAF. DFT was used to calculate the energy for the frontier molecular orbitals such as HOMO, LUMO, energy gap, and other reactivity parameters. The charge-density distributions associated with anti-cancer activity were investigated using frontier molecular-orbital surfaces and electrostatic potentials (EPs). Similarly, the chosen compounds demonstrated potentially some interesting pharmacological properties (bioavailability) and pharmacokinetic properties according to drug-likeness rules. As a result, the selected compounds were identified as possible V600E-BRAF hits with eventually superior pharmacokinetic properties, and they could be proposed as promising cancer drug candidates.

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Design, Synthesis, Biological Evaluation and Molecular Modeling of Novel 1H-Pyrazolo[3,4-d]pyrimidine Derivatives As BRAF(V600E) and VEGFR-2 Dual Inhibitors

Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold As Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies

Design, Synthesis, and Biological Evaluation of Pyrazole Derivatives Containing Acetamide Bond As Potential BRAFV600E Inhibitors.

Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAF(V⁶⁰⁰E) inhibitors.

Synthesis, Biological Evaluation of Novel 4,5-Dihydro-2h-pyrazole 2-Hydroxyphenyl Derivatives As BRAF Inhibitors.

Design and Biological Evaluation of Novel Triaryl Pyrazoline Derivatives with Dioxane Moiety for Selective BRAFV600E Inhibition.

Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAFV600E inhibitors

Synthesis, Biological Evaluation and 3D-QSAR Studies of Novel 4,5-Dihydro-1h-pyrazole Niacinamide Derivatives As BRAF Inhibitors

Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.

Design, Synthesis and Biological Evaluation of Novel Benzo-Α-pyrone Containing Piperazine Derivatives As Potential BRAFV600E Inhibitors

Insights into the structure-activity relationship of pyrimidine-sulfonamide analogues for targeting BRAF V600E protein

Molecular description of pyrimidine-based inhibitors with activity against FAK combining 3D-QSAR analysis, molecular docking and molecular dynamics

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Design, Synthesis and Biological Evaluation of (1,3-Diphenyl-1h-pyrazol-4-yl) Methyl Benzoate Derivatives As Potential BRAFV600E Inhibitors

Design, Synthesis and Biological Evaluation of Novel (E)-Α-benzylsulfonyl Chalcone Derivatives As Potential BRAF Inhibitors.

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Pyrrolo[3,2-d]pyrimidine Derivatives As Type II Kinase Insert Domain Receptor (KDR) Inhibitors: CoMFA and CoMSIA Studies

Modification, Biological Evaluation and 3D QSAR Studies of Novel 2-(1,3-diaryl- 4,5-Dihydro-1h-pyrazol-5-yl)phenol Derivatives As Inhibitors of B-Raf Kinase.

Investigation of Novel Imidazole Analogues with Terminal Sulphonamides as Potential V600E-BRAF Inhibitors Through Computational Approaches

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors